US National Institute on Drug Abuse (NIDA) to Conduct Clinical Study on Biotie's Nepicastat in Cocaine Dependence
Under the agreement, NIDA and Biotie will investigate the safety and efficacy of Biotie's nepicastat (SYN117) in the treatment of cocaine dependence. NIDA will fund the conduct of a randomized, double-blind placebo-controlled trial, lasting 11 weeks, in 180 treatment-seeking cocaine-dependent subjects using nepicastat supplied by Biotie. The study will be conducted at approximately 12 US clinics specializing in the treatment of drug dependence.
"We are pleased to be working with NIDA and some of the world's most renowned investigators of treatments for cocaine dependence," said Timo Veromaa, Chief Executive Officer of Biotie. "There is currently no approved treatment for cocaine dependence, a condition which exacts a heavy toll on individuals, their families and society as a whole."
Biotie and NIDA have previously collaborated on preclinical studies evaluating potential pharmacokinetic and pharmacodynamic interactions between nepicastat and drugs of abuse. Biotie retains rights to nepicastat and will be able to use data from studies conducted with NIDA to support future potential regulatory submissions.
The trial is expected to start in H1 2012 and take approximately two years to complete.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.